Triheptanoin

(Dojolvi)

Triheptanoin

Drug updated on 11/14/2023

Dosage FormLiquid (oral: 100% w/w of triheptanoin)
Drug ClassMedium-chain triglycerides
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Product Monograph / Prescribing Information

Document TitleYearSource
Dojolvi (triheptanoin) Prescribing Information.2021Ultragenyx Pharmaceutical Inc., Novato, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines